Nektar Therapeutics NKTR
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover NKTR, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
-
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
-
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
-
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
-
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
-
Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated
-
Nektar Regains Rezpegaldesleukin Rights as Eli Lilly Deal Ends
Trading Information
- Previous Close Price
- $1.37
- Day Range
- $1.32–1.43
- 52-Week Range
- $0.41–1.75
- Bid/Ask
- $1.24 / $1.47
- Market Cap
- $260.74 Mil
- Volume/Avg
- 976,212 / 2.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.14
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 137
- Website
- https://www.nektar.com
Comparables
Valuation
|
Metric
|
NKTR
|
TGTX
|
ALVR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.83 | — |
Price/Book Value | 2.18 | 13.33 | 0.59 |
Price/Sales | 3.14 | 8.98 | — |
Price/Cash Flow | — | 39.40 | — |
Price/Earnings
NKTR
TGTX
ALVR
Financial Strength
|
Metric
|
NKTR
|
TGTX
|
ALVR
|
|---|---|---|---|
Quick Ratio | 5.97 | 5.00 | 6.49 |
Current Ratio | 6.45 | 5.92 | 6.61 |
Interest Coverage | −10.65 | 2.04 | — |
Quick Ratio
NKTR
TGTX
ALVR
Profitability
|
Metric
|
NKTR
|
TGTX
|
ALVR
|
|---|---|---|---|
Return on Assets (Normalized) | −20.94% | 19.44% | −52.75% |
Return on Equity (Normalized) | −49.86% | 54.76% | −66.34% |
Return on Invested Capital (Normalized) | −29.93% | 35.76% | −59.54% |
Return on Assets
NKTR
TGTX
ALVR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yysrsmjsd | Rlbpn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lnkzgjf | Snmlf | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sdvyzgr | Htytvb | $98.8 Bil | |
MRNA
| Moderna Inc | Svrzdbv | Hxnpb | $38.8 Bil | |
ARGX
| argenx SE ADR | Wmdfzfs | Ngdr | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Yflbdmdd | Glyv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dmprygrzv | Pdtdyt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Clhxvwqk | Ppvqlr | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Grdgnhvj | Whyfdl | $12.4 Bil | |
INCY
| Incyte Corp | Nwdjhrz | Cyygz | $11.9 Bil |